{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HR%2B%2FHER2-+Breast+Cancer&page=4", "query": { "condition": "HR+/HER2- Breast Cancer", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 195, "total_pages": 20, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HR%2B%2FHER2-+Breast+Cancer&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HR%2B%2FHER2-+Breast+Cancer&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-10T09:59:35.672Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04225117", "title": "A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced or Metastatic Malignant Solid Tumors" ], "interventions": [ { "name": "enfortumab vedotin", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 329, "start_date": "2020-03-10", "completion_date": "2027-03-31", "has_results": true, "last_update_posted_date": "2026-09-23", "last_synced_at": "2026-10-10T09:59:35.672Z", "location_count": 29, "location_summary": "Tucson, Arizona • San Francisco, California • Aurora, Colorado + 23 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Tallahassee", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04225117" }, { "nct_id": "NCT07109726", "title": "A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer", "Endometrial Cancer", "Ovarian Cancer", "Lung Squamous Cell Carcinoma", "Head and Neck Squamous Cell Carcinoma", "Esophageal Squamous Cell Carcinoma", "Solid Tumor", "Cervical Cancer" ], "interventions": [ { "name": "TER-2013", "type": "DRUG" }, { "name": "Fulvestrant injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Terremoto Biosciences Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 205, "start_date": "2025-09-23", "completion_date": "2029-02-28", "has_results": false, "last_update_posted_date": "2026-09-17", "last_synced_at": "2026-10-10T09:59:35.672Z", "location_count": 17, "location_summary": "Duarte, California • Irvine, California • Orlando, Florida + 14 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Zion", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07109726" }, { "nct_id": "NCT06515470", "title": "Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "BTX-9341", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biotheryx, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 82, "start_date": "2024-07-03", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2025-06-06", "last_synced_at": "2026-10-10T09:59:35.672Z", "location_count": 6, "location_summary": "Rochester, Minnesota • Omaha, Nebraska • Houston, Texas + 3 more", "locations": [ { "city": "Rochester", "state": "Minnesota" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" }, { "city": "West Valley City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT06515470" }, { "nct_id": "NCT06756932", "title": "BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hormone-receptor-positive Breast Cancer", "HER2-negative Breast Cancer", "Metastatic Breast Cancer" ], "interventions": [ { "name": "BGB-21447", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "BGB-43395", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeOne Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2025-02-04", "completion_date": "2027-07-30", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-10-10T09:59:35.672Z", "location_count": 3, "location_summary": "Iowa City, Iowa • Houston, Texas • Seattle, Washington", "locations": [ { "city": "Iowa City", "state": "Iowa" }, { "city": "Houston", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT06756932" }, { "nct_id": "NCT04443348", "title": "Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Triple Negative Breast Cancer", "Hormone Receptor Positive (HR+), HER2-negative Breast Cancer", "Biopsy-proven, Positive Lymph Node(s)" ], "interventions": [ { "name": "Radiation Therapy Boost", "type": "RADIATION" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "Laura M. Spring, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2020-12-16", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-07-13", "last_synced_at": "2026-10-10T09:59:35.672Z", "location_count": 10, "location_summary": "Washington D.C., District of Columbia • Baltimore, Maryland • Boston, Massachusetts + 6 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04443348" }, { "nct_id": "NCT06058377", "title": "Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage III Breast Cancer AJCC v8", "HER2-Negative Breast Carcinoma", "Hormone Receptor-Positive Breast Carcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Genetic Testing", "type": "OTHER" }, { "name": "Mammography", "type": "PROCEDURE" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3680, "start_date": "2023-11-27", "completion_date": "2032-05-31", "has_results": false, "last_update_posted_date": "2026-10-09", "last_synced_at": "2026-10-10T09:59:35.672Z", "location_count": 558, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 429 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06058377" }, { "nct_id": "NCT05252416", "title": "(VELA) Study of BLU-222 in Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "HR+ Breast Cancer", "CCNE1 Amplification", "HER2-negative Breast Cancer", "Ovarian Cancer", "Endometrial Cancer", "Gastric Cancer", "Esophageal Adenocarcinoma", "Carcinosarcoma" ], "interventions": [ { "name": "BLU-222", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Blueprint Medicines Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2022-04-07", "completion_date": "2025-07-04", "has_results": false, "last_update_posted_date": "2025-11-28", "last_synced_at": "2026-10-10T09:59:35.672Z", "location_count": 19, "location_summary": "Little Rock, Arkansas • San Francisco, California • Stanford, California + 13 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05252416" }, { "nct_id": "NCT06726148", "title": "Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced HR+/HER2- Breast Cancer", "Advanced CCNE1-amplified Solid Tumors", "Extensive-stage Small Cell Lung Cancer" ], "interventions": [ { "name": "ECI830", "type": "DRUG" }, { "name": "ribociclib", "type": "DRUG" }, { "name": "fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 280, "start_date": "2025-04-03", "completion_date": "2028-09-25", "has_results": false, "last_update_posted_date": "2026-08-27", "last_synced_at": "2026-10-10T09:59:35.672Z", "location_count": 8, "location_summary": "Los Angeles, California • Fort Myers, Florida • Boston, Massachusetts + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06726148" }, { "nct_id": "NCT05996107", "title": "Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, HR+/HER2- Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Ribociclib", "type": "DRUG" }, { "name": "Postoperative Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 30, "start_date": "2024-02-27", "completion_date": "2030-10", "has_results": false, "last_update_posted_date": "2026-07-15", "last_synced_at": "2026-10-10T09:59:35.672Z", "location_count": 3, "location_summary": "Ann Arbor, Michigan • Wyoming, Michigan • Cleveland, Ohio", "locations": [ { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Wyoming", "state": "Michigan" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05996107" }, { "nct_id": "NCT03988114", "title": "A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Nonsteroidal Aromatase Inhibitor (NSAI)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2019-09-16", "completion_date": "2023-03-23", "has_results": false, "last_update_posted_date": "2019-09-06", "last_synced_at": "2026-10-10T09:59:35.672Z", "location_count": 70, "location_summary": "Daphne, Alabama • Tempe, Arizona • Fountain Valley, California + 60 more", "locations": [ { "city": "Daphne", "state": "Alabama" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Highland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03988114" } ] }